Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BioCardia, Inc. logo — a leader in the development of comprehensive solutions for c...

BioCardia, Inc.

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies

Founded 2002 United States Sunnyvale, United States 24 employees Post Ipo Equity Biotechnology, Health and Wellness

General Information

Company Name BioCardia, Inc.
Founded Year 2002
Location United States Sunnyvale, United States +1
Founders / Decision Makers
Team member
Employees 24
Industries Biotechnology, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when BioCardia, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BioCardia, Inc.

BioCardia, Inc. is a clinical-stage regenerative medicine company founded in 2002, specializing in the development of novel therapeutics for cardiovascular diseases. The company's slogan, "a leader in the development of comprehensive solutions for cardiovascular regenerative therapies," reflects its commitment to addressing large unmet medical needs in this field. BioCardia's proprietary biotherapeutic solutions, CardiAMP™ and CardiALLO™ therapies, have shown compelling clinical results, supported by rigorous data in the field, particularly with intramyocardial delivery of marrow-derived cells. These advancements are made possible by the company's Helix™ transendocardial delivery systems and Morph® vascular access products, which enable the development of other promising biotherapeutic programs. The last investment in BioCardia, Inc. was a Post-IPO Equity investment on 30 August 2024. The investors involved in this latest round of funding are currently undisclosed. The company operates within the biotechnology and health and wellness industries, positioning itself as a significant player in the cardiovascular regenerative therapies market. With its innovative therapies and strong clinical results, BioCardia is well-positioned to continue making strides in addressing unmet medical needs in cardiovascular diseases.

Taxonomy: regenerative medicine, cardiovascular therapy, clinical-stage research, therapeutics development, transendocardial delivery systems, vascular access products

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 30 Aug 2024
Post-IPO Equity •••••• - 16 Nov 2023
Post-IPO Equity •••••• - 15 Dec 2022
Post-IPO Equity •••••• - 16 Dec 2020
Post-IPO Equity •••••• - 17 Jun 2020

View All 6 Funding Rounds

BioCardia, Inc. Alternatives & Competitors

BioCardia, Inc. vs
Cardurion Pharmaceuticals
Cardurion Pharmaceuticals United States

Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics

Series B
80 employees
Biotechnology, Health Care
BioCardia, Inc. vs
XenoTherapeutics
XenoTherapeutics United States

Advancing Xenotransplantation to Therapeutic Reality

9 employees
Biotechnology
BioCardia, Inc. vs
Partikula LLC
Partikula LLC United States

Partikula leverages its exclusive chemical engineering technologies to create compounds that specifi...

Series Unknown
2-10 employees
Biotechnology, Health Care

FAQ About BioCardia, Inc.

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies
BioCardia, Inc. was founded in 2002.
BioCardia, Inc. is headquartered in Sunnyvale, United States.
BioCardia, Inc. operates in the following industries: Biotechnology, Health and Wellness.
BioCardia, Inc. has approximately 24 employees.
BioCardia, Inc. has completed 6 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to BioCardia, Inc. include Cardurion Pharmaceuticals, XenoTherapeutics, Partikula LLC, ARCA biopharma, Biotest Farmaceutica Ltda.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioCardia, Inc. and Cardurion Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BioCardia, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy